Hematopoietic growth factors: Personalization of risks and benefits

Shannon Puhalla; Saveri Bhattacharya; Nancy E. Davidson

doi:10.1016/j.molonc.2012.03.001

Hematopoietic growth factors: Personalization of risks and benefits

Shannon Puhalla, Saveri Bhattacharya, Nancy E. Davidson

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

Original language	English (US)
Pages (from-to)	237-241
Number of pages	5
Journal	Molecular oncology
Volume	6
Issue number	2
DOIs	https://doi.org/10.1016/j.molonc.2012.03.001
State	Published - Apr 2012

Keywords

Erythropoietin stimulating agents (ESAs)
Granulocyte colony stimulating factors (GCSF)
Pegfilgastrim

ASJC Scopus subject areas

Molecular Medicine
Genetics
Oncology
Cancer Research

Access to Document

10.1016/j.molonc.2012.03.001

Fingerprint Dive into the research topics of 'Hematopoietic growth factors: Personalization of risks and benefits'. Together they form a unique fingerprint.

Cite this

@article{2bc51187012d42738a47a36714893667,

title = "Hematopoietic growth factors: Personalization of risks and benefits",

abstract = "A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.",

keywords = "Erythropoietin stimulating agents (ESAs), Granulocyte colony stimulating factors (GCSF), Pegfilgastrim",

author = "Shannon Puhalla and Saveri Bhattacharya and Davidson, {Nancy E.}",

year = "2012",

month = apr,

doi = "10.1016/j.molonc.2012.03.001",

language = "English (US)",

volume = "6",

pages = "237--241",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Hematopoietic growth factors

T2 - Personalization of risks and benefits

AU - Puhalla, Shannon

AU - Bhattacharya, Saveri

AU - Davidson, Nancy E.

PY - 2012/4

Y1 - 2012/4

N2 - A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

AB - A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

KW - Erythropoietin stimulating agents (ESAs)

KW - Granulocyte colony stimulating factors (GCSF)

KW - Pegfilgastrim

UR - http://www.scopus.com/inward/record.url?scp=84860445233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860445233&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2012.03.001

DO - 10.1016/j.molonc.2012.03.001

M3 - Review article

C2 - 22497867

AN - SCOPUS:84860445233

VL - 6

SP - 237

EP - 241

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -